In the last few years there have been significant advances in chemotherapy for prostate cancer. Until recently chemotherapy was not recommended. Recent trials have demonstrated a survival benefit for metastatic prostatic cancer when chemotherapy is used with hormone treatment.
The patients most likely to benefit are those with extensive metastatic disease.
Taxol chemotherapy is the most common approach.
There are several new agents also used in advanced disease when hormonal treatment is no longer effective. These agents include Abiraterone, Enzalutamide, Sipuleucel-T, Cabazitaxel
The optimal sequencing and combinations have yet to be determined and treatment is individualised.
Management of advanced disease now often involves consultation with medical oncologist.